Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
188 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015', provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Attention Deficit Hyperactivity Disorder (ADHD) Overview 8 Therapeutics Development 9 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview 9 Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis 10 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies 11 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes 15 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies 20 Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes 24 Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 25 Alcobra Ltd 25 Amarantus Bioscience Holdings, Inc. 26 APeT Holding BV 27 Arbor Pharmaceuticals, LLC. 28 BCWorld Pharm Co. Ltd. 29 Collegium Pharmaceutical, Inc. 30 Curemark, LLC 31 Domain Therapeutics SA 32 DURECT Corporation 33 H. Lundbeck A/S 34 Heptares Therapeutics Limited 35 Highland Therapeutics, Inc. 36 Hisamitsu Pharmaceutical Co., Inc. 37 Integrative Research Laboratories Sweden AB 38 Intra-Cellular Therapies, Inc. 39 KemPharm, Inc. 40 Luc Therapeutics, Inc. 41 Medgenics Inc. 42 Merck & Co., Inc. 43 Neos Therapeutics, Inc. 44 NeuroDerm Ltd. 45 Neurovance, Inc. 46 P2D Bioscience 47 Polleo Pharma Limited 48 Reviva Pharmaceuticals Inc. 49 Samyang Biopharmaceuticals Corporation 50 Shire Plc 51 Signature Therapeutics, Inc 52 Sunovion Pharmaceuticals Inc. 53 Supernus Pharmaceuticals, Inc. 54 Taisho Pharmaceutical Holdings Co., Ltd. 55 Tris Pharma, Inc. 56 Vernalis Plc 57 Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 58 Assessment by Monotherapy Products 58 Assessment by Combination Products 59 Assessment by Target 60 Assessment by Mechanism of Action 63 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 (nicotine + opipramol hydrochloride) - Drug Profile 69 amfetamine XR - Drug Profile 70 AR-08 - Drug Profile 71 BCWPE-003 - Drug Profile 72 BLI-1008 - Drug Profile 73 BNC-375 - Drug Profile 74 CB-8411 - Drug Profile 75 centanafadine IR - Drug Profile 76 centanafadine SR - Drug Profile 77 CM-4612 - Drug Profile 78 CTX-1301 - Drug Profile 79 CTX-1302 - Drug Profile 80 dasotraline - Drug Profile 81 dextroamphetamine - Drug Profile 83 dextroamphetamine MR - Drug Profile 84 eltoprazine - Drug Profile 85 etiguanfacine - Drug Profile 87 guanfacine hydrochloride ER - Drug Profile 88 histamine dihydrochloride - Drug Profile 90 HTL-1071 - Drug Profile 91 IRL-752 - Drug Profile 92 ITI-214 - Drug Profile 93 KP-415 CR - Drug Profile 94 lisdexamfetamine dimesylate - Drug Profile 96 Metadoxine ER - Drug Profile 100 methylphenidate hydrochloride - Drug Profile 102 methylphenidate hydrochloride - Drug Profile 103 methylphenidate hydrochloride MR - Drug Profile 104 methylphenidate hydrochloride SR - Drug Profile 106 methylphenidate hydrochloride XR - Drug Profile 107 MGS-0028 - Drug Profile 108 molindone hydrochloride ER - Drug Profile 109 NFC-1 - Drug Profile 110 niacinamide CR - Drug Profile 111 NT-0201 - Drug Profile 112 P-001 - Drug Profile 113 PBF-509 - Drug Profile 114 PD-2005 - Drug Profile 116 PD-2007 - Drug Profile 117 PFR-08001 - Drug Profile 118 PFR-8026 - Drug Profile 119 RP-5063 - Drug Profile 120 SHP-465 - Drug Profile 121 Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile 122 Small Molecules to Agonize GPR88 for Attention Deficit Hyperactivity Disorder and Schizophrenia - Drug Profile 123 Small Molecules to Agonize NMDA2D for ADHD - Drug Profile 124 Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 125 Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 126 Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile 127 TRI-102 - Drug Profile 128 V-81444 - Drug Profile 129 viloxazine hydrochloride - Drug Profile 130 vortioxetine hydrobromide - Drug Profile 131 VU-0238429 - Drug Profile 134 Attention Deficit Hyperactivity Disorder (ADHD) - Recent Pipeline Updates 135 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 170 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 175 Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 176 Featured News & Press Releases 176 Appendix 183 Methodology 183 Coverage 183 Secondary Research 183 Primary Research 183 Expert Panel Validation 183 Contact Us 183 Disclaimer 184
List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2015 13 Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2015 14 Number of Products under Development by Companies, H2 2015 16 Number of Products under Development by Companies, H2 2015 (Contd..1) 17 Number of Products under Development by Companies, H2 2015 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2015 19 Comparative Analysis by Late Stage Development, H2 2015 20 Comparative Analysis by Clinical Stage Development, H2 2015 21 Comparative Analysis by Early Stage Development, H2 2015 22 Comparative Analysis by Unknown Stage Development, H2 2015 23 Products under Development by Companies, H2 2015 24 Products under Development by Companies, H2 2015 (Contd..1) 25 Products under Development by Companies, H2 2015 (Contd..2) 26 Products under Development by Companies, H2 2015 (Contd..3) 27 Products under Investigation by Universities/Institutes, H2 2015 28 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H2 2015 29 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015 30 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H2 2015 31 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC., H2 2015 32 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co. Ltd., H2 2015 33 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H2 2015 34 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H2 2015 35 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Domain Therapeutics SA, H2 2015 36 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H2 2015 37 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H2 2015 38 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Limited, H2 2015 39 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics, Inc., H2 2015 40 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2015 41 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H2 2015 42 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 43 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H2 2015 44 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics, Inc., H2 2015 45 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Medgenics Inc., H2 2015 46 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co., Inc., H2 2015 47 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H2 2015 48 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H2 2015 49 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance, Inc., H2 2015 50 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H2 2015 51 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Polleo Pharma Limited, H2 2015 52 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H2 2015 53 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Samyang Biopharmaceuticals Corporation, H2 2015 54 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2015 55 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Signature Therapeutics, Inc, H2 2015 56 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015 57 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H2 2015 58 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2015 59 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma, Inc., H2 2015 60 Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vernalis Plc, H2 2015 61 Assessment by Monotherapy Products, H2 2015 62 Assessment by Combination Products, H2 2015 63 Number of Products by Stage and Target, H2 2015 65 Number of Products by Stage and Mechanism of Action, H2 2015 68 Number of Products by Stage and Route of Administration, H2 2015 70 Number of Products by Stage and Molecule Type, H2 2015 72 Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Recent Pipeline Updates, H2 2015 139 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2015 174 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..1), H2 2015 175 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..2), H2 2015 176 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..3), H2 2015 177 Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..4), H2 2015 178 Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2015 179
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
